This study examines eye movements and the pupil's response to light in progressive supranuclear palsy (PSP), comparing to Parkinson's disease and control subjects without neurological disease. Computerized measures of eye movements and pupil changes will be used. Subjects will also receive an eye exam to rule out other eye diseases. The goal of this study is to use subtle changes in eye movements and the pupil's response to light for earlier diagnosis of PSP.
A seizure is a common sign or symptom characterized by abnormal electrical activity in the brain that affects about 10% of individuals in the population at some point in their lives. Although most are self-limited and transient, seizures sometimes fail to respond to medications and may even progress despite administration of medications. When these seizures are characterized by spread to both sides of the brain (become generalized), aggressive management with sedating medications is warranted. However, if seizures remain confined to one side of the brain (remain focal), the risks associated with high doses of sedating medications often outweighs the potential benefits of stopping the seizure. This has led to a search for other therapies that can more effectively target and control focal seizures without causing significant sedation, damage to other organs, or medication interactions. Transcranial magnetic stimulation (TMS) is one such therapy that has shown promise in case series and case reports, although no clinical controlled trial has yet been published to validate its efficacy in patients with severe seizures. In addition, TMS has been shown to be safe for use in epilepsy and other disorders.
We aim to evaluate the efficacy of TMS in patients with severe seizures that are not controlled with medications.
The purpose of this study is to examine the accuracy of wearable technology to detect and characterize smoking behavior. The study consists of one visit and will last approximately one hour. We are seeking adult (? 18 years old) male and female smokers to participate. Compensation is available for those that qualify.
Individuals with anxiety disorders are approximately twice as likely as the general population to experience alcohol addiction and vice versa. The affinity toward addiction is especially high in the case of posttraumatic stress disorder (PTSD). Animal and human work has suggested that the neurocircuitry largely overlaps in both the expression and extinction of fear and craving. This study involves utilizing one session of non-invasive brain stimulation (repetitive transcranial magnetic stimulation) to enhance extinction learning as measured with functional magnetic resonance imaging, in both healthy individuals and those with PTSD and alcohol addiction. While this is a single session study, the goal of this study is two identify promising new brain targets to be used therapeutically for individuals suffering from PTSD and alcohol addiction.
We are studying the potential influence of non-invasive brain stimulation on the areas of the brain that control muscle movements. This study involves questionnaires, measurements of muscle movements with non-invasive electromyography (EMG) and transcranial magnetic stimulation. While we are looking for healthy volunteers, these findings could help us develop treatments for people struggling with anxiety and depression.
Fast brain MRI scans can often replace the need for a CT scan for evaluation of ventriculoperitoneal shunts, and evaluation of brain fluid spaces. The use of fbMRI scans for other types of neurologic disorders has not well studied. We aim to study the use of fbMRI for diagnosis of a vast array of neurologic disorders by comparing them with a routine brain MRI in children. We hypothesize that a well-designed fbMRI scan will be able to diagnose many more neurologic diseases than we currently think, decreasing the need for sedation and anesthesia in the pediatric patient population.
This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement on brains of youth (ages 15-19) using magnetic resonance imaging (MRI). 50 adolescents will receive, in a counterbalanced order, a 10-day course of NAC 1200 mg twice daily and a subsequent 10-day course of matched placebo twice daily, separated by 11 days. Urine and blood samples will be collected at baseline and urine samples again before and after each course of medication treatment. Participants will receive a 1- hour MRI scan at baseline and after each treatment trial.
You/your child could be eligible to participate if he or she is:
Between the ages of 15 and 19.
Has consumed alcohol.
Participants must provide informed consent and youth under 18 must have parental consent to participate.
Compensation is available to those who qualify.
Subjects are being asked to volunteer for a research study because they have their first anaplastic astrocytoma (AA) tumor progression (worsening) or recurrence.
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Eflornithine is an experimental drug that the United States Food and Drug Administration (FDA) has not approved it for use by the general public. Lomustine has been approved by the FDA in the United States for this patient population.